Evaluation of Ovarian Tumors by Proton Magnetic Resonance Spectroscopy at Three Tesla

Abstract

Spectroscopy of ovarian masses can be recorded at 3.0 T with acceptable spectral quality and good signal-to-noise ratio. There are stringent technical considerations to be considered in obtaining good spectral quality. Further experience with a larger and more biologically variable range of tumors needs to be undertaken to determine the final clinical utility of this technique, but initial results from this small cohort are promising.

Adiabatic localized correlation spectroscopy (AL‐COSY): Application in muscle and brain

“…This can be achieved by introducing a second frequency dimension, thus facilitating analysis and improving reliability (3)(4)(5)(6)(7)(8). Concentrations of various biochemicals derived from spectroscopic exams are known to be correlated with the status of health or disease (9)(10)(11)(12)(13)(14).…”

In vivo magnetic resonance spectroscopy for ovarian cancer diagnostics: quantification by the fast Padé transform

“…Due to the diversity of units as well as of the procedures, these data could not be pooled. Metabolite concentration ratios of Cho to Cr were reported in two of the studies [51,54]. In both studies, the Cho/Cr concentration ratio was significantly higher in cancerous ovarian lesions than in the benign ovaries.…”

“…The main metabolite peaks resolved were: lipid (Lip) at 1.3 ppm (parts per million), an inverted lactate (Lac) doublet also at around 1.3 ppm, creatine (Cr) at 3.0 ppm, choline (Cho) at 3.2 ppm or total Cho between 3.14 and 3.34 ppm and Lip at 5.2 ppm. In addition, a peak with resonance frequency between 2.0 and 2.1 ppm was reported by some authors [48][49][50][51][52]54]. Based upon in vitro analysis, this peak was found to be comprised of N-acetyl aspartate (NAA) as well as N-acetyl groups from glycoproteins and/or glycolipids [50].…”

“…The common methodologic feature of all these in vivo studies was that the MRS time signals were processed by the fast Fourier transform (FFT) as is the conventional practice, with eventual post-processing via fitting in some instances, such as in Refs. [40,45,51,52,54].…”

“…Several investigative teams have applied in vivo MRS with the aim of improving ovarian cancer diagnostics. We performed a systematic search 3 of the literature and found published results for 134 malignant ovarian lesions, 114 benign ovarian lesions and 3 lesions of the ovary that were classified as "borderline" (BL), using in vivo proton MRS time signals encoded via clinical (1.5 or 3 T) magnetic resonance (MR) scanners [40,[43][44][45][46][47][48][49][50][51][52][53][54][55]. Appendix 1 provides a summary of the clinical aspects and design of these studies, with salient information concerning the reported MRS data.…”